• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Top 10 Pharmaceutical - Industry, Financial and SWOT Analysis Product Image

Global Top 10 Pharmaceutical - Industry, Financial and SWOT Analysis

  • ID: 1540059
  • February 2011
  • Region: Global
  • 129 Pages
  • Datamonitor

The Global Top 10 Pharmaceutical Companies report profiles the leading players in the pharmaceutical market worldwide. The sector consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

The report analyzes the sector in terms of market value, market share, market segmentation, key drivers and resistors, trends and competitive positioning. It includes details of the top 10 companies in the industry along with five-year financial analysis and in-depth SWOT profiles.

Key features of this report

- Market dynamics in the global pharmaceutical sector during the period 2009–14
- The market's key drivers and resistors
- Trends in the pharmaceutical sector
- Identification and analysis of the top 10 pharmaceutical players globally
- Details of the performance of the top 10 companies during 2005–09

Scope of this report

- Analyze the global top 10 pharmaceutical and the sector overall using key industry metrics, including market value, market shares, market segmentation and growth forecasts
- Assess the intensity of the competition in the industry using the five forces model, covering the degree READ MORE >

Executive Summary
- Industry analysis
- Industry definition
- Research highlights
- Top 10 companies landscape
- Market Value
- Market Forecast
- Market Segmentation: Product
- Market Segmentation: Geographic
- Five Forces Analysis
- Summary
- Buyer power
- Supplier power
- New entrants
- Substitutes
- Rivalry
- Top 10 Companies Landscape
- Overview
- Revenue analysis
- Financial performance analysis
- Company Reports
Pfizer
F. Hoffmann-La Roche
Novartis
GlaxoSmithKline
Sanofi-Aventis
AstraZeneca
Abbott Laboratories
Merck & Co.
Eli Lilly and Company
Bristol-Myers Squibb Company
Five-Year Financial Information
Pfizer
F. Hoffman-La Roche
Novartis
GlaxoSmithKline
Sanofi-Aventis
AstraZeneca
Abbott Laboratories
Merck & Co.
Eli Lilly and Company
Bristol-Myers Squibb Company

Appendix

List of Figures
Figure 1: Global pharmaceuticals market ($ billion), 2005–09
Figure 2: Global pharmaceuticals market forecast ($ billion), 2009–14
Figure 3: Global pharmaceuticals market segmentation: product (% share), 2009
Figure 4: Global pharmaceuticals market segmentation: geography (% share), 2009
Figure 5: Forces driving competition in the global pharmaceuticals market, 2009
Figure 6: Drivers of buyer power in the global pharmaceuticals market, 2009
Figure 7: Drivers of supplier power in the global pharmaceuticals market, 2009
Figure 8: Factors influencing the likelihood of new entrants in the global pharmaceuticals market, 2009
Figure 9: Factors influencing the threat of substitutes in the global pharmaceuticals market, 2009
Figure 10: Drivers of degree of rivalry in the global pharmaceuticals market, 2009
Figure 11: Revenues of global top 10 pharmaceutical companies ($m), FY2009
Figure 12: Revenue growth of the global top 10 pharmaceutical companies, FY2007–09
Figure 13: Operating performance analysis, FY2009
Figure 14: Net profit analysis, FY2009

List of Tables
Table 1: Global pharmaceutical market ($ billion), 2005–09
Table 2: Global pharmaceuticals market forecast ($ billion), 2009–14
Table 3: Global pharmaceuticals market segmentation: product (% share), 2009
Table 4: Global pharmaceuticals market segmentation: geography (% share), 2009
Table 5: Revenues and sales of global top 10 pharmaceutical companies ($m), FY2009
Table 6: Revenue growth of global top 10 pharmaceutical companies, FY2007–09
Table 7: Key financials of the global top 10 pharmaceutical companies, FY2009
Table 8: Key industry-specific ratios, FY2009
Table 9: Pfizer: financial and operational highlights, 2005–09 ($m)
Table 10: Pfizer: key industry-specific ratios, 2005–09
Table 11: F. Hoffman-La Roche: financial and operational highlights, 2005–09 ($m)
Table 12: F. Hoffman-La Roche: key industry-specific ratios, 2005–09
Table 13: Novartis: financial and operational highlights, 2005–09 ($m)
Table 14: Novartis: key industry-specific ratios, 2005–09
Table 15: GlaxoSmithKline: financial and operational highlights, 2005–09 ($m)
Table 16: GlaxoSmithKline: key industry-specific ratios, 2005–09
Table 17: Sanofi-Aventis: financial and operational highlights, 2005–09 ($m)
Table 18: Sanofi-Aventis: key industry-specific ratios, 2005–09
Table 19: AstraZeneca: financial and operational highlights, 2005–09 ($m)
Table 20: AstraZeneca: key industry-specific ratios, 2005–09
Table 21: Abbott Laboratories: financial and operational highlights, 2005–09 ($m)
Table 22: Abbott Laboratories: key industry-specific ratios, 2005–09
Table 23: Merck & Co.: financial and operational highlights, 2005–09 ($m)
Table 24: Merck & Co.: key industry-specific ratios, 2005–09
Table 25: Eli Lilly and Company: financial and operational highlights, 2005–09 ($m)
Table 26: Eli Lilly and Company: key industry-specific ratios, 2005–09
Table 27: Bristol-Myers Squibb Company: financial and operational highlights, 2005–09 ($m)
Table 28: Bristol-Myers Squibb Company: key industry-specific ratios, 2005–09

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos